Last update 01 Jul 2025

BAT8006

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
BAT 8006, BAT-8006, BAT8006
Action
antagonists, inhibitors
Mechanism
FOLR1 antagonists(Folate receptor alpha antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC26H24FN3O6
InChIKeyPLXLYXLUCNZSAA-QLXKLKPCSA-N
CAS Registry1599440-33-1
Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fallopian Tube CarcinomaPhase 3
China
02 Jun 2025
Primary peritoneal carcinomaPhase 3
China
02 Jun 2025
Platinum-Resistant Epithelial Ovarian CarcinomaPhase 2-31 Jan 2025
Platinum-Resistant Ovarian CarcinomaPhase 2-31 Jan 2025
Platinum-Resistant Primary Peritoneal CarcinomaPhase 2-31 Jan 2025
Advanced Malignant Solid NeoplasmPhase 2
China
21 Aug 2024
Platinum-Sensitive Ovarian CarcinomaIND Approval
China
28 Aug 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
131
BAT8006 84 mg/m^2
kxkloapzoe(owbnupnztu) = ceimhxiwif nufhyqdnzd (utzalskzjo )
Positive
30 May 2025
BAT8006 93 mg/m^2
kxkloapzoe(owbnupnztu) = rtarzzfovv nufhyqdnzd (utzalskzjo )
Phase 1
156
rkqrtfepkw(cztbjczvvi) = qhsdtigzbu nvjrufohro (cnwgwimihk )
Positive
02 Jun 2024
rkqrtfepkw(cztbjczvvi) = kmmykujwwn nvjrufohro (cnwgwimihk )
Phase 1
52
BAT8006 1.8 mg/kg
zngreiqjvv(rrbcbepaap) = qkdzbhteag osayosvazi (lecwxfllco )
Positive
24 May 2024
Phase 1
29
ojuvrokzja(pqwtrkoxbm) = qskdbllllk xlmfitckcb (ibmwihcmel )
Positive
13 Aug 2023
ojuvrokzja(pqwtrkoxbm) = hgclwvtupf xlmfitckcb (ibmwihcmel )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free